ESR2 and neoplasm: Given that ERβ expression significantly reduces with disease progression, activation of the ERβ function by use of the specific agonist, OSU-ERb-12, could help limit the CSC subpopulation, thereby, eliminating the source of tumor metastasis and recurrence.